Author: admin

A new report released by Hevolution Foundation highlights that extending the number of years people live in good health is now one of the defining challenges for economies and societies worldwide. The second edition of the Global Healthspan Report presents new evidence that aging, once seen as an inevitable decline, can be managed through science, policy, and innovation to drive sustainable growth and wellbeing. Drawing on two global surveys and extensive investment data, the report positions healthspan, the years of life spent in good health, as both a catalyst for scientific and economic progress. The findings reveal the magnitude of…

Sponsored By: This podcast features Dr. George Busby discussing his work on polygenic risk scores (PRS) and their expanding role in precision medicine. He reflects on how he became interested in PRS, recent advances in methylation risk scores (MRS), and the potential of integrating PRS and MRS to improve disease prediction. The conversation highlights his breast cancer study in Colombian women, exploring its hypothesis, findings, and global relevance. Busby also addresses challenges in translating genomic research into clinical practice, efforts to enhance predictive models, and how technological evolution continues to drive innovation and future directions in genomic medicine.   This…

Bathed in the golden glow of the midnight sun, the frozen expanse of the Svalbard archipelago stretches out in endless silence around Arwyn Edwards. To the naked eye, these wind-scoured glaciers appear to be sterile deserts. Yet, immediately beneath the crunch of Edwards’ boots, the ice teems with an invisible and thriving biosphere, lush with bacteria, fungi, and viruses. Scientists have estimated that the glaciers and ice sheets around the globe could contain as many as 1029 cells.1“The biomass that’s stored within the planet’s glacial ice is broadly comparable to the amount of biomass that you have in the soils…

Sarcopenia—reduced muscle mass, strength, and function—is often associated with aging and frequently impacts quality of life in the elderly. Individuals with sarcopenia are also prone to further injury that can lead to drastic health declines. “It is absolutely crucial that we are able to develop strategies to maintain muscle as we age,” proclaimed Alessandra Sacco, PhD, the dean of the Sanford Burnham Prebys Graduate School of Biomedical Sciences and a professor in the Center for Cardiovascular and Muscular Diseases. “The progressive loss of skeletal muscle mass and function are indicators of poor survival in patients.” Sacco is the senior author…

Researchers studied the genomic characteristics of bacteria, archaea, and eukaryotes to trace the history of eukaryotic cell origins.Image credit:©iStock.com, Rasi BhadramaniApproximately four billion years ago, the first forms of life emerged on Earth. For eons, biological life consisted of prokaryotic organisms, either early bacteria or archaea. Determining when eukaryotic cells emerged has been challenging. Many hypotheses point to complex, eukaryotic life emerging around two billion years ago, coinciding with the introduction of the mitochondria into cells shortly after Earth’s atmosphere became more oxygen-rich.However, a new study led by researchers at the University of Bristol suggests that the eukaryotic cell began…

Credit: Westend61 / Getty Images In a landmark effort to decode the cellular roots of childhood neurodevelopmental disorders (NDDs), researchers have built one of the largest publicly available stem-cell resources of its kind—an expansive biobank of induced pluripotent stem cells (iPSCs) and human brain organoids derived from genetically diverse patients. The atlas, published in Cell Stem Cell, accurately reflects the cellular phenotypes, providing data to understand how many genetic changes affect human brain development. NDDs are present in approximately 25% of all chronic pediatric disorders, collectively imposing an enormous toll, accounting for over $400 billion in annual U.S. healthcare costs…

EMMI is used across Terray’s entire pipeline, identifying and optimizing novel chemical scaffolds. [Terray] Terray Therapeutics has achieved its first discovery milestone in the company’s multi-target collaboration with Bristol Myers Squibb (BMS). Under the terms of the agreement, which began in 2023, Terray will discover and develop small molecule compounds against a set of targets nominated by BMS. BMS will subsequently assume responsibility for development and commercialization.  While therapeutic details of the milestone have not been disclosed, Terray describes the target as “novel and difficult to drug,” and representative of the company’s Experimentation Meets Machine Intelligence (EMMI) platform.   The AI drug discovery biotech was founded in 2018 by CEO Jacob Berlin, PhD, based on an ultraminiaturized chip technology, about the size of…

Q | Write a brief introduction to yourself including the lab you work in and your research background. My name is Sarah Libring and I am a biomedical engineer working under Cynthia Reinhart-King at Rice University. I am studying breast cancer metastasis and the ability of different breast cancer cells to condition fibroblasts at distant organs to support metastatic tumor growth. Our research goal is to understand mechanobiology in the metastatic cascade and reduce the burden of metastatic disease.Q | How did you first get interested in science and/or your field of research? In high school, I was part of…

Scientists refine microglia replacement as a potential therapy for neurodegenerative disease – and progress is accelerating. Front-line innovation in neurodegenerative disease rarely arrives quickly; however, microglia replacement, once a speculative idea rooted in preclinical immunology, has crossed the translational divide with unusual speed. Five years after efficient replacement strategies were first demonstrated in mice, the same logic has been used to halt progression of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) in human patients. The approach – known as MISTER, or microglia intervention strategy for therapy and enhancement by replacement – rests on the observation that pathogenic microglia…

Sponsored content brought to you by With the precision of monoclonal antibodies and the potency of small-molecular payloads, antibody-drug conjugates (ADC) are promising cancer therapeutics. As of this year, there are 19 ADC drugs available on the market, with more than 200 in clinical trials. However, getting more of these treatments on the market requires addressing unique manufacturing challenges. These include strict containment due the hazardous payload; use of organic solvents, which may extract unwanted components from the single-use plastics; and reliable analytical control of the drug-antibody ratio (DAR), which is an important critical quality attribute. Repligen’s portfolio of single-use…